Extension of the randomized, double-blind, placebo-controlled single ascending dose study to assess the safety and tolerability of AP30663 in healthy subjects.
Latest Information Update: 30 Aug 2021
At a glance
- Drugs AP-30663 (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Acronyms CHDR2008
- Sponsors Acesion Pharma
- 30 Aug 2021 New trial record